Piramal Pharma Stock Climbs 14% on Return to Profit and Higher Growth Target
Piramal Pharma swung back to a quarterly profit, more than doubled operating earnings and lifted its FY27 revenue growth outlook, Moody's reports.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Shares of the Indian drugmaker Piramal Pharma rose 14% on Wednesday, October 28, according to Moody's. The company posted a net profit of Rs 5.58 crore for the September quarter, compared with a loss of Rs 99.2 crore a year earlier. Revenue climbed 28% to Rs 2,617 crore, while EBITDA rose to Rs 348.7 crore from Rs 158.7 crore, lifting the margin by 550 basis points to 13.3%.
Management credited higher capacity utilisation, operating leverage and disciplined execution. All three business verticals grew: revenue at the CDMO unit rose 36%, complex hospital generics gained 32%, and consumer healthcare added 13%. The company now expects FY27 revenue growth of 19-20% and a meaningful improvement in profitability. Net debt still stands at Rs 4,859 crore and remains a key consideration.
why it matters
The move reflects a shift from loss to profit and a stronger outlook, which matter to shareholders and to peers watching Indian CDMO growth. Net debt of Rs 4,859 crore is the main counterweight for investors weighing the rally, so the story is company-specific rather than a broad market driver.
market impact
Акции Piramal Pharma: сильные результаты и повышенный прогноз поддерживают бумагу
- Piramal Pharma shares pressure up — return to profit and a raised revenue growth outlook
tags
instruments
sources
- Piramal Pharma Shares Jump 14% As FY27 Revenue Growth Outlook Raised To 20% — Moody's, 28 October 2026 at 11:51 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗